(NASDAQ: OCUL, "Ocular", the "Company"), a biopharmaceutical company committed to redefining the retina experience, outlined exceptional clinical progress across its registrational program for AXPAXLI ...

SOL-R, Ocular’s second registrational trial of AXPAXLI™ in wet AMD, as of January 10, 2024 First wet AMD registrational trial ...

Diabetic retinopathy is a common complication in people with type 1 and type 2 diabetes, progressing from mild, moderate, and ...

Macular neovascularization within 1 year of avacincaptad pegol therapy worsens outcomes compared with patients without ...

In this video, Clement K. Chan, MD, FACS, recaps a lecture from the Macula Society symposium at the AAO meeting.In the Arnall Patz Lecture, Richard F. Spaide, MD, discussed advancements in modern OCT ...

Across all DME patients dosed to date, 4D-150 continues to be well tolerated with no intraocular inflammation observed at any timepoint or dose ...

The following is a summary of “Effect of siponimod on retinal thickness, a marker of neurodegeneration, in participants with SPMS: Findings from the EXPAND OCT substudy,” published in the January 2025 ...

Regeneron Pharmaceuticals, Inc. faces a securities fraud class action after shares of the company plunged $84.59 on Oct. 31, 2024, wiping out about $9 billion of market ...

Over 537 million people globally suffer from diabetes, with 227 million in Asia Pacific. More than half may develop diabetic ...

GA management involves identifying at-risk patients, assessing visual function, and referring for treatment when necessary.

The beginning of the new CPD cycle means it is time to prepare a new professional development plan (PDP) and sketch out areas ...

The Miami Valley Veterans Museum at 2245 South County Road 25-A in Troy is proud to announce its January program as well as the programs for 2025. The monthly January program will be on Jan. 8, 9 a.m.